Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiosurgery | 7 | 2022 | 399 | 0.800 |
Why?
|
| Brachytherapy | 3 | 2017 | 132 | 0.520 |
Why?
|
| Androgen Antagonists | 2 | 2008 | 91 | 0.500 |
Why?
|
| Prostatic Neoplasms | 3 | 2008 | 978 | 0.460 |
Why?
|
| Trigeminal Neuralgia | 3 | 2004 | 15 | 0.300 |
Why?
|
| Goserelin | 1 | 2008 | 8 | 0.270 |
Why?
|
| Tosyl Compounds | 1 | 2008 | 17 | 0.270 |
Why?
|
| Nelson Syndrome | 1 | 2007 | 5 | 0.270 |
Why?
|
| Dysuria | 1 | 2007 | 3 | 0.270 |
Why?
|
| Leuprolide | 1 | 2008 | 21 | 0.270 |
Why?
|
| Pituitary ACTH Hypersecretion | 1 | 2007 | 12 | 0.270 |
Why?
|
| Proton Therapy | 1 | 2007 | 15 | 0.270 |
Why?
|
| Acromegaly | 1 | 2007 | 17 | 0.260 |
Why?
|
| Anilides | 1 | 2008 | 84 | 0.260 |
Why?
|
| Nitriles | 1 | 2008 | 207 | 0.240 |
Why?
|
| Prostate | 1 | 2007 | 158 | 0.240 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2008 | 193 | 0.240 |
Why?
|
| Prostate-Specific Antigen | 1 | 2006 | 161 | 0.230 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2006 | 1149 | 0.150 |
Why?
|
| Radiation Oncology | 1 | 2020 | 82 | 0.150 |
Why?
|
| Near Miss, Healthcare | 1 | 2018 | 12 | 0.140 |
Why?
|
| Papillomavirus Infections | 1 | 2022 | 344 | 0.140 |
Why?
|
| Dermatology | 1 | 2020 | 130 | 0.140 |
Why?
|
| Risk Management | 1 | 2018 | 82 | 0.130 |
Why?
|
| Patient Safety | 2 | 2018 | 356 | 0.130 |
Why?
|
| Head and Neck Neoplasms | 1 | 2022 | 561 | 0.130 |
Why?
|
| Health Plan Implementation | 1 | 2018 | 141 | 0.130 |
Why?
|
| Safety Management | 1 | 2018 | 125 | 0.130 |
Why?
|
| Medical Errors | 1 | 2018 | 119 | 0.130 |
Why?
|
| 46, XX Disorders of Sex Development | 1 | 2016 | 7 | 0.130 |
Why?
|
| Mullerian Ducts | 1 | 2016 | 17 | 0.120 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2016 | 11 | 0.120 |
Why?
|
| Gallbladder Neoplasms | 1 | 2016 | 20 | 0.120 |
Why?
|
| Radiotherapy | 1 | 2017 | 204 | 0.120 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2020 | 641 | 0.110 |
Why?
|
| Hospitals | 1 | 2018 | 732 | 0.100 |
Why?
|
| Aged, 80 and over | 6 | 2008 | 8333 | 0.090 |
Why?
|
| Neoadjuvant Therapy | 2 | 2022 | 465 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2007 | 3904 | 0.080 |
Why?
|
| Middle Aged | 8 | 2008 | 36215 | 0.070 |
Why?
|
| Aged | 7 | 2008 | 26153 | 0.070 |
Why?
|
| Bromocriptine | 1 | 2007 | 31 | 0.070 |
Why?
|
| Growth Hormone-Secreting Pituitary Adenoma | 1 | 2007 | 12 | 0.070 |
Why?
|
| Octreotide | 1 | 2007 | 23 | 0.070 |
Why?
|
| Urinary Catheterization | 1 | 2007 | 35 | 0.070 |
Why?
|
| Growth Hormone | 1 | 2007 | 91 | 0.060 |
Why?
|
| Protons | 1 | 2007 | 96 | 0.060 |
Why?
|
| Remission Induction | 1 | 2007 | 307 | 0.060 |
Why?
|
| Morbidity | 1 | 2008 | 322 | 0.060 |
Why?
|
| Adult | 8 | 2016 | 40777 | 0.060 |
Why?
|
| Male | 9 | 2008 | 72842 | 0.060 |
Why?
|
| Humans | 15 | 2022 | 145474 | 0.060 |
Why?
|
| Massachusetts | 1 | 2006 | 180 | 0.060 |
Why?
|
| Hydrocortisone | 1 | 2007 | 298 | 0.060 |
Why?
|
| Adenoma | 1 | 2007 | 218 | 0.060 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2007 | 317 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2007 | 969 | 0.050 |
Why?
|
| Risk | 1 | 2007 | 919 | 0.050 |
Why?
|
| Combined Modality Therapy | 1 | 2008 | 1266 | 0.050 |
Why?
|
| Brain Stem | 1 | 2004 | 98 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2006 | 1374 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2007 | 11772 | 0.040 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2002 | 187 | 0.040 |
Why?
|
| Glioma | 2 | 2004 | 429 | 0.040 |
Why?
|
| Female | 8 | 2017 | 78844 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2006 | 5423 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2002 | 499 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2020 | 351 | 0.040 |
Why?
|
| Adolescent | 2 | 2007 | 22529 | 0.030 |
Why?
|
| Pain | 1 | 2003 | 789 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2002 | 1217 | 0.030 |
Why?
|
| Quality of Life | 3 | 2004 | 3204 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2017 | 149 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2006 | 6013 | 0.030 |
Why?
|
| Congenital Abnormalities | 1 | 2016 | 109 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2022 | 1505 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 2004 | 1329 | 0.030 |
Why?
|
| Skin | 1 | 2020 | 753 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2017 | 339 | 0.030 |
Why?
|
| Apoptosis | 1 | 2002 | 2440 | 0.030 |
Why?
|
| Patient Selection | 1 | 2017 | 738 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2017 | 899 | 0.020 |
Why?
|
| Risk Factors | 1 | 2006 | 10885 | 0.020 |
Why?
|
| United States | 2 | 2020 | 16098 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 2017 | 849 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2018 | 1295 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2007 | 17291 | 0.020 |
Why?
|
| Trigeminal Nerve Diseases | 1 | 2004 | 3 | 0.010 |
Why?
|
| Hypesthesia | 1 | 2004 | 21 | 0.010 |
Why?
|
| Nerve Compression Syndromes | 1 | 2004 | 22 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 2382 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2004 | 288 | 0.010 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2002 | 54 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2002 | 162 | 0.010 |
Why?
|
| Neoplasms | 1 | 2017 | 2906 | 0.010 |
Why?
|
| Cell Death | 1 | 2002 | 382 | 0.010 |
Why?
|
| Survivors | 1 | 2004 | 523 | 0.010 |
Why?
|
| Recurrence | 1 | 2004 | 1138 | 0.010 |
Why?
|
| Survival Rate | 1 | 2004 | 2090 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2002 | 1443 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2002 | 3542 | 0.010 |
Why?
|